Skip to main content
Erschienen in: Strahlentherapie und Onkologie 7/2014

01.07.2014 | Original article

Schedule-dependent interaction between vinblastine and irradiation in experimental sarcoma

verfasst von: Dr. Maja Cemazar, Ph.D., Tanja Dolinsek, B.sc., Tina Kosjek, Ph.D., Bostjan Markelc, Ph.D., Gregor Sersa, Ph.D., Veronika Kloboves, Ph.D., Primoz Strojan, Ph.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Prolonged vinblastine (VLB) infusion and irradiation (IR) lead to favourable results in certain tumours types; however the underlying biological mechanisms of interaction are not well known. The aim of our study was to evaluate the dose- and time-dependent interactions between split-dose VLB treatment (mimicking prolonged infusion) and IR of sarcoma SA-1 tumours in A/J mice.

Methods

Antitumor effectiveness of different VLB-IR schedules was determined by a tumour growth delay assay, the VLB amount in the tumours by liquid chromatography coupled to mass spectrometry and DNA cell cycle analysis.

Results

A positive antitumor effect was obtained when tumours were irradiated immediately after the first (0 h) or second (4 h) injection of VLB treatment, despite the lower amount of VLB in the tumours as well as decreased number of cells in the IR-sensitive G2M phase at these times points as opposed to the second half of VLB split-dose scheduling.

Conclusion

Preferential binding of VLB to microtubules (with consequent lack of available VLB to bind to DNA where it acts as a radioprotector) and the absence of radiobiologically relevant hypoxia are presumably leading to the observed therapeutic benefit of applying IR at the beginning of the prolonged VLB infusion.
Literatur
1.
Zurück zum Zitat Auersperg M, Soba E, Vraspir-Porenta O (1977) Intravenous chemotherapy with syndronization in advanced cancer of oral cavity and oropharynx. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 90:149–159PubMedCrossRef Auersperg M, Soba E, Vraspir-Porenta O (1977) Intravenous chemotherapy with syndronization in advanced cancer of oral cavity and oropharynx. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 90:149–159PubMedCrossRef
2.
Zurück zum Zitat Auersperg M, Us-Krasovec M, Lamovec J et al (1989) Chemotherapy—a new approach to the treatment of verrucous carcinoma. Radiol Iugosl 23:387–392 Auersperg M, Us-Krasovec M, Lamovec J et al (1989) Chemotherapy—a new approach to the treatment of verrucous carcinoma. Radiol Iugosl 23:387–392
3.
Zurück zum Zitat Auersperg M, Us-Krasovec M, Petric G et al (1990) Results of combined modality treatment in poorly differentiated and anaplastic thyroid carcinoma. Wien Klin Wochenschr 102:267–270PubMed Auersperg M, Us-Krasovec M, Petric G et al (1990) Results of combined modality treatment in poorly differentiated and anaplastic thyroid carcinoma. Wien Klin Wochenschr 102:267–270PubMed
4.
Zurück zum Zitat Cemazar M, Sersa G, Auersperg M (1997) Antitumor effectiveness of bolus versus split dose vinblastine treatment in EAT tumors in mice. Anticancer Res 17:4553–4556PubMed Cemazar M, Sersa G, Auersperg M (1997) Antitumor effectiveness of bolus versus split dose vinblastine treatment in EAT tumors in mice. Anticancer Res 17:4553–4556PubMed
5.
Zurück zum Zitat Hau J, Poulsen OM (1988) Doses for laboratory animals based on metabolic rate. Scand J Lab Anim Sci 15:81 Hau J, Poulsen OM (1988) Doses for laboratory animals based on metabolic rate. Scand J Lab Anim Sci 15:81
6.
Zurück zum Zitat Eich HT, Kriz J, Schmidberger H et al (2013) The German evidence-based guidelines for Hodgkinʼs lymphoma. Aspects for radiation oncologists. Strahlenther Onkol 189:445–447PubMedCrossRef Eich HT, Kriz J, Schmidberger H et al (2013) The German evidence-based guidelines for Hodgkinʼs lymphoma. Aspects for radiation oncologists. Strahlenther Onkol 189:445–447PubMedCrossRef
7.
Zurück zum Zitat Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ (1993) Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 29A:1320–1324PubMedCrossRef Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ (1993) Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 29A:1320–1324PubMedCrossRef
8.
Zurück zum Zitat Hill SA, Sampson LE, Chaplin DJ (1995) Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 63:119–123PubMedCrossRef Hill SA, Sampson LE, Chaplin DJ (1995) Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 63:119–123PubMedCrossRef
9.
Zurück zum Zitat Jaffe N, Auersperg M, Us-Krasovec M et al (1991) Novel therapeutic strategies for the treatment of rhabdomysarcoma and soft tissue sarcomas: observations with arterial infusion chemotherapy. In: Maurer HM (ed) Rhabdomyosarcoma and related tumors in children and adolescents. CRC press, Boca Raton, pp 243–260 Jaffe N, Auersperg M, Us-Krasovec M et al (1991) Novel therapeutic strategies for the treatment of rhabdomysarcoma and soft tissue sarcomas: observations with arterial infusion chemotherapy. In: Maurer HM (ed) Rhabdomyosarcoma and related tumors in children and adolescents. CRC press, Boca Raton, pp 243–260
10.
Zurück zum Zitat Jordan MA (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2:1–17PubMedCrossRef Jordan MA (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2:1–17PubMedCrossRef
11.
Zurück zum Zitat Kosjek T, Dolinsek T, Gramec D et al (2013) Determination of vinblastine in tumor tissue with liquid chromatography—high resolution mass spectrometry. Talanta 116:887–893PubMedCrossRef Kosjek T, Dolinsek T, Gramec D et al (2013) Determination of vinblastine in tumor tissue with liquid chromatography—high resolution mass spectrometry. Talanta 116:887–893PubMedCrossRef
12.
Zurück zum Zitat Kragelj B, Zaletel-Kragelj L, Sedmak B et al (2005) Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 75:44–47PubMedCrossRef Kragelj B, Zaletel-Kragelj L, Sedmak B et al (2005) Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 75:44–47PubMedCrossRef
13.
Zurück zum Zitat Otto F (1990) DAPI staining of fixed cells for high-resolution flow cytometry of nuclear DNA. Methods Cell Biol 33:105–110PubMedCrossRef Otto F (1990) DAPI staining of fixed cells for high-resolution flow cytometry of nuclear DNA. Methods Cell Biol 33:105–110PubMedCrossRef
14.
Zurück zum Zitat Pogacnik A, Us-Krasovec M, Bracko M (1993) Preparation of fine needle aspiration biopsy samples for flow cytometric analysis. Anal Quant Cytol Histol 15:298–302PubMed Pogacnik A, Us-Krasovec M, Bracko M (1993) Preparation of fine needle aspiration biopsy samples for flow cytometric analysis. Anal Quant Cytol Histol 15:298–302PubMed
15.
Zurück zum Zitat Rajagopalan R, Ranjan SK, Nair CK (2003) Effect of vinblastine sulfate on gamma-radiation-induced DNA single-strand breaks in murine tissues. Mutat Res 536:15–25PubMedCrossRef Rajagopalan R, Ranjan SK, Nair CK (2003) Effect of vinblastine sulfate on gamma-radiation-induced DNA single-strand breaks in murine tissues. Mutat Res 536:15–25PubMedCrossRef
17.
Zurück zum Zitat Sersa G, Cemazar M, Sentjurc M et al (1994) Effects of vinblastine on cell membrane fluidity and the growth of SA-1 tumor in mice. Cancer Lett 79:53–60PubMedCrossRef Sersa G, Cemazar M, Sentjurc M et al (1994) Effects of vinblastine on cell membrane fluidity and the growth of SA-1 tumor in mice. Cancer Lett 79:53–60PubMedCrossRef
18.
Zurück zum Zitat Sersa G, Krzic M, Sentjurc M et al (2001) Reduced tumor oxygenation by treatment with vinblastine. Cancer Res 61:4266–4271PubMed Sersa G, Krzic M, Sentjurc M et al (2001) Reduced tumor oxygenation by treatment with vinblastine. Cancer Res 61:4266–4271PubMed
19.
Zurück zum Zitat Sersa G, Kranjc S, Cemazar M (2000) Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int J Radiat Oncol Biol Phys 46:1037–1041PubMedCrossRef Sersa G, Kranjc S, Cemazar M (2000) Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int J Radiat Oncol Biol Phys 46:1037–1041PubMedCrossRef
20.
Zurück zum Zitat Strojan P, Soba E, Budihna M, Auersperg M (2005) Radiochemotherapy with vinblastine, methotrexate, and Bleomycin in the treatment of verrucous carcinoma of the head and neck. J Surg Oncol 92:278–283PubMedCrossRef Strojan P, Soba E, Budihna M, Auersperg M (2005) Radiochemotherapy with vinblastine, methotrexate, and Bleomycin in the treatment of verrucous carcinoma of the head and neck. J Surg Oncol 92:278–283PubMedCrossRef
21.
Zurück zum Zitat Sui M, Fan W (2005) Combination of gamma-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis. Int J Radiat Oncol Biol Phys 61:1151–1158PubMedCrossRef Sui M, Fan W (2005) Combination of gamma-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis. Int J Radiat Oncol Biol Phys 61:1151–1158PubMedCrossRef
22.
Zurück zum Zitat Sui M, Zhang H, Di X et al (2012) G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy. Radiother Oncol 104:243–248PubMedCentralPubMedCrossRef Sui M, Zhang H, Di X et al (2012) G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy. Radiother Oncol 104:243–248PubMedCentralPubMedCrossRef
Metadaten
Titel
Schedule-dependent interaction between vinblastine and irradiation in experimental sarcoma
verfasst von
Dr. Maja Cemazar, Ph.D.
Tanja Dolinsek, B.sc.
Tina Kosjek, Ph.D.
Bostjan Markelc, Ph.D.
Gregor Sersa, Ph.D.
Veronika Kloboves, Ph.D.
Primoz Strojan, Ph.D.
Publikationsdatum
01.07.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 7/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0645-x

Weitere Artikel der Ausgabe 7/2014

Strahlentherapie und Onkologie 7/2014 Zur Ausgabe

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.